Potential and real ‘antineoplastic’ and metabolic effect of metformin in diabetic and nondiabetic postmenopausal females

Abstract

ABSTRACT  Aim: The goal of this study was to determine if the single nucleotide polymorphisms marking potential sensitivity to metformin (MF) correlate with hormone-metabolic status as well as with actual response to MF in postmenopausal cancer patients with or without Type 2 diabetes mellitus and in diabetics without cancer. Patients & methods: The carriage of ten different SNPs was evaluated in all patients by PCR, and hormone-metabolic status was estimated by anthropometry, ELISA and enzyme colorimetric assays. The response to daily 1–1.7 g of MF was studied based on hormone-metabolic parameters and indirect end points (endometrium thickness, mammographic breast density). Results & conclusion: The changes in evaluated ‘antineoplastic’ and metabolic response marker values were seen in 33.3 and 61.8% of the cases, respectively. Several genetic markers were found that showed an inclination to less frequent ‘antineoplastic’ or more frequent metabolic response to MF which may be helpful in further studies of this drug in cancer patients.